Nanoparticle Formulation Market

Nanoparticle Formulation Market (Technologies and Services) - By Type of Nanoparticle (Organic (Polymeric, Lipid Nanoparticles, Viral & Others), Inorganic Nanoparticles and Carbon-based Nanoparticles), Scale of Operation and Key Geographies: Industry Trends and Global Forecasts, 2023-2035

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    297

  • Pages
    246

  • View Count
    11639

Table Of Contents

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Nanoparticles
3.3. Classification of Nanoparticles
3.3.1. Organic Nanoparticles
3.3.2. Inorganic Nanoparticles
3.3.3. Carbon-based Nanoparticles
3.4. Methods of Nanoparticle Formulation
3.5. Applications of Nanoparticle-based Systems
3.6. Challenges associated with Nanoparticle Formulation
3.7. Need for Outsourcing Nanoparticle Formulation
3.8 Concluding Remarks

4. TECHNOLOGY LANDSCAPE
4.1. Chapter Overview
4.2. Nanoparticle Formulation: Technology Landscape
4.2.1. Analysis by Type of Nanoparticle(s) Formulated
4.2.2. Analysis by Type of Organic Nanoparticle(s) Formulated
4.2.3. Analysis by Type of Inorganic Nanoparticle(s) Formulated
4.2.4. Analysis by Type of Molecule(s) Delivered
4.2.5. Analysis by Therapeutic Area(s)
4.2.6. Analysis by Compatible Dosage Form(s)
4.2.7. Analysis by Route(s) of Administration

4.3. Nanoparticle Formulation: Technology Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Company Size and Location of Headquarters
4.3.5. Most Active Players: Analysis by Number of Technologies

5. SERVICE PROVIDERS LANDSCAPE
5.1. Chapter Overview
5.2. Nanoparticle Formulation: Service Providers Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarters
5.2.5. Analysis by Location of Facilities
5.2.6. Analysis by Type of Service Provider(s)
5.2.7. Analysis by Type of Nanoparticle(s) Formulated
5.2.7.1. Analysis by Type of Organic Nanoparticle(s) Formulated
5.2.7.2. Analysis by Type of Inorganic Nanoparticle(s) Formulated

5.2.8. Analysis by Type of Service Provider(s) and Type of Nanoparticle(s) Formulated
5.2.9. Analysis by Service(s) Offered
5.2.10. Analysis by Company Size and Service(s) Offered
5.2.11. Analysis by Scale of Operation
5.2.12. Analysis by Application Area(s)

6. TECHNOLOGY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions / Key Parameters
6.3. Methodology
6.4. Technology Competitiveness Analysis
6.4.1. Nanoparticle Formulation Technologies Offered by Players based in North America
6.4.1.1. Nanoparticle Formulation Technologies Offered by Small Players based in North America
6.4.1.2. Nanoparticle Formulation Technologies Offered by Mid-sized and Large Players based in North America

6.4.2. Nanoparticle Formulation Technologies Offered by Players based in Europe
6.4.3. Nanoparticle Formulation Technologies Offered by Players based in Asia-Pacific, Middle East and North Africa, and Rest of the World

7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions / Key Parameters
7.3. Methodology
7.4. Company Competitiveness Analysis
7.4.1. Nanoparticle Formulation Service Providers based in North America
7.4.2. Nanoparticle Formulation Service Providers based in Europe
7.4.3. Nanoparticle Formulation Service Providers based in Asia-Pacific, and Middle East and North Africa

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Ascension Sciences
8.2.1. Company Overview
8.2.2. Technology Portfolio
8.2.3. Service Portfolio
8.2.4. Recent Developments and Future Outlook

8.3. DIANT Pharma
8.3.1. Company Overview
8.3.2. Technology Portfolio
8.3.3. Service Portfolio
8.3.4. Recent Developments and Future Outlook

8.4. ExonanoRNA
8.4.1. Company Overview
8.4.2. Technology Portfolio
8.4.3. Service Portfolio
8.4.4. Recent Developments and Future Outlook

8.5. Nanoform
8.5.1. Company Overview
8.5.2. Technology Portfolio
8.5.3. Service Portfolio
8.5.4. Recent Developments and Future Outlook

8.6. NanoVation Therapeutics
8.6.1. Company Overview
8.6.2. Technology Portfolio
8.6.3. Service Portfolio
8.6.4. Recent Developments and Future Outlook

8.7. NanoVelos
8.7.1. Company Overview
8.7.2. Technology Portfolio
8.7.3. Service Portfolio
8.7.4. Recent Developments and Future Outlook

8.8. NTT Biopharma
8.8.1. Company Overview
8.8.2. Technology Portfolio
8.8.3. Service Portfolio
8.8.4. Recent Developments and Future Outlook

8.9. Organoid-X BioTech
8.9.1. Company Overview
8.9.2. Technology Portfolio
8.9.3. Service Portfolio
8.9.4. Recent Developments and Future Outlook

8.10. Vaxinano
8.10.1. Company Overview
8.10.2. Technology Portfolio
8.10.3. Service Portfolio
8.10.4. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Nanoparticle Formulation Technologies and Services: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Location of Headquarters of Partner
9.3.6. Analysis by Type of Partnership and Location of Headquarters of Partner
9.3.7. Most Active Players: Analysis by Number of Partnerships
9.3.8. Analysis by Geography
9.3.8.1. Intercontinental and Intracontinental Deals
9.3.8.2. Local and International Deals

10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Nanoparticle Formulation Domain: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Type of Patent and Publication Year
10.3.3. Analysis by Geography
10.3.4. Analysis by CPC Symbols
10.3.5. Analysis by Type of Organization
10.3.6. Leading Industry Players: Analysis by Number of Patents

10.4. Patent Benchmark Analysis
10.4.1. Analysis by Patent Characteristics

10.5. Patent Valuation Analysis

11. NANOPARTCLE EVALUATION FRAMEWORK
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Organic Nanoparticles
11.3.1. Number of Clinical Trials
11.3.2. Extent of Innovation
11.3.3. Trends in Research Activity
11.3.4. Current Global Competition
11.3.5. Nanoparticle Evaluation Framework: Organic Nanoparticles

11.4. Inorganic Nanoparticles
11.4.1. Number of Clinical Trials
11.4.2. Extent of Innovation
11.4.3. Trends in Research Activity
11.4.4. Current Global Competition
11.4.5. Nanoparticle Evaluation Framework: Inorganic Nanoparticles

11.5. Carbon-based Nanoparticles
11.5.1. Number of Clinical Trials
11.5.2 Extent of Innovation
11.5.3. Trends in Research Activity
11.5.4. Current Global Competition
11.5.5. Nanoparticle Evaluation Framework: Carbon-based Nanoparticles
11.5.6. Nanoparticle Evaluation Framework: Concluding Remarks

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Global Nanoparticle Formulation Services Market, 2023-2035
12.4. Nanoparticle Formulation Services Market: Analysis by Type of Nanoparticle Formulated
12.4.1. Nanoparticle Formulation Services Market: Analysis by Type of Organic Nanoparticle Formulated
12.4.1.1. Nanoparticle Formulation Services Market for Polymeric Nanoparticles, 2023-2035
12.4.1.2. Nanoparticle Formulation Services Market for Lipid Nanoparticles, 2023-2035
12.4.1.3. Nanoparticle Formulation Services Market for Viral Nanoparticles, 2023-2035
12.4.1.4. Nanoparticle Formulation Services Market for Protein-based Nanoparticles, 2023-2035
12.4.1.5. Nanoparticle Formulation Services Market for Other Organic Nanoparticles, 2023-2035
12.4.2. Nanoparticle Formulation Services Market: Analysis by Inorganic Nanoparticle Formulated
12.4.3. Nanoparticle Formulation Services Market: Analysis by Carbon-based Nanoparticle Formulated

12.5. Nanoparticle Formulation Services Market: Analysis by Scale of Operation
12.5.1. Nanoparticle Formulation Services Market for Preclinical Operations, 2023-2035
12.5.2. Nanoparticle Formulation Services Market for Clinical Operations, 2023-2035
12.5.3. Nanoparticle Formulation Services Market for Commercial Operations, 2023-2035

12.6. Nanoparticle Formulation Services Market: Analysis by Key Geographical Regions
12.6.1. Nanoparticle Formulation Services Market in North America, 2023-2035
12.6.2. Nanoparticle Formulation Services Market in Europe, 2023-2035
12.6.3. Nanoparticle Formulation Services Market in Asia-Pacific, 2023-2035
12.6.4. Nanoparticle Formulation Services Market in Middle East and North Africa, 2023-2035
12.6.5. Nanoparticle Formulation Services Market in Latin America, 2023-2035

13. CASE STUDY: TECHNOLOGY LICENSING DEALS
13.1. Chapter Overview
13.2. Recent Technology Licensing Deals
13.3. Concluding Remarks

14. CONCLUSION

15. EXECUTIVE INSIGHTS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Technology Landscape
Figure 2.2 Executive Summary: Service Providers Landscape
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Patent Analysis
Figure 2.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Key Benefits and Limitations of Nanoparticle-based Systems
Figure 3.2 Classification of Nanoparticles
Figure 3.3 Applications of Nanoparticle-based Systems
Figure 4.1 Nanoparticle Formulation Technologies: Distribution by Type of Nanoparticle(s) Formulated
Figure 4.2 Nanoparticle Formulation Technologies: Distribution by Type of Organic Nanoparticle(s) Formulated
Figure 4.3 Nanoparticle Formulation Technologies: Distribution by Type of Inorganic Nanoparticle(s) Formulated
Figure 4.4 Nanoparticle Formulation Technologies: Distribution by Type of Molecule(s) Delivered
Figure 4.5 Nanoparticle Formulation Technologies: Distribution by Therapeutic Area(s)
Figure 4.6 Nanoparticle Formulation Technologies: Distribution by Compatible Dosage Form(s)
Figure 4.7 Nanoparticle Formulation Technologies: Distribution by Route(s) of Administration
Figure 4.8 Nanoparticle Formulation Technology Developers: Distribution by Year of Establishment
Figure 4.9 Nanoparticle Formulation Technology Developers: Distribution by Company Size
Figure 4.10 Nanoparticle Formulation Technology Developers: Distribution by Location of Headquarters
Figure 4.11 Nanoparticle Formulation Technology Developers: Distribution by Company Size and Location of Headquarters
Figure 4.12 Most Active Players: Distribution by Number of Technologies
Figure 5.1 Nanoparticle Formulation Service Providers: Distribution by Year of Establishment
Figure 5.2 Nanoparticle Formulation Service Providers: Distribution by Company Size
Figure 5.3 Nanoparticle Formulation Service Providers: Distribution by Location of Headquarters
Figure 5.4 Nanoparticle Formulation Service Providers: Distribution by Company Size and Location of Headquarters
Figure 5.5 Nanoparticle Formulation Service Providers: Distribution by Location of Facilities
Figure 5.6 Nanoparticle Formulation Service Providers: Distribution by Type of Service Provider(s)
Figure 5.7 Nanoparticle Formulation Service Providers: Distribution by Type of Nanoparticle(s) Formulated
Figure 5.8 Nanoparticle Formulation Service Providers: Distribution by Type of Organic Nanoparticle(s) Formulated
Figure 5.9 Nanoparticle Formulation Service Providers: Distribution by Type of Inorganic Nanoparticle(s) Formulated
Figure 5.10 Nanoparticle Formulation Service Providers: Distribution by Type of Service Provider(s) and Type of Nanoparticle(s) Formulated
Figure 5.11 Nanoparticle Formulation Service Providers: Distribution by Type of Service(s) Offered
Figure 5.12 Nanoparticle Formulation Service Providers: Distribution by Company Size and Type of Service(s) Offered
Figure 5.13 Nanoparticle Formulation Service Providers: Distribution by Scale of Operation
Figure 5.14 Nanoparticle Formulation Service Providers: Distribution by Application Area(s)
Figure 6.1 Technology Competitiveness Analysis: Nanoparticle Formulation Technologies Offered by Small Players based in North America
Figure 6.2 Technology Competitiveness Analysis: Nanoparticle Formulation Technologies Offered by Mid-sized and Large Players based in North America
Figure 6.3 Technology Competitiveness Analysis: Nanoparticle Formulation Technologies Offered by Players based in Europe
Figure 6.4 Technology Competitiveness Analysis: Nanoparticle Formulation Technologies Offered by Players based in Asia-Pacific, Middle East and North Africa, and Rest of the World
Figure 7.1 Company Competitiveness Analysis: Nanoparticle Formulation Service Providers based in North America
Figure 7.2 Company Competitiveness Analysis: Nanoparticle Formulation Service Providers based in Europe
Figure 7.3 Company Competitiveness Analysis: Nanoparticle Formulation Service Providers based in Asia-Pacific, and Middle East and North Africa
Figure 8.1 Ascension Sciences: Service Portfolio
Figure 8.2 DIANT Pharma: Service Portfolio
Figure 8.3 ExonanoRNA: Service Portfolio
Figure 8.4 Nanoform: Service Portfolio
Figure 8.5 NanoVation Therapeutics: Service Portfolio
Figure 8.6 NanoVelos: Service Portfolio
Figure 8.7 NTT Biopharma: Service Portfolio
Figure 8.8 Organoid-X BioTech: Service Portfolio
Figure 8.9 Vaxinano: Service Portfolio
Figure 9.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.5 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Headquarters of Partner
Figure 9.7 Most Active Players: Distribution by Number of Partnerships
Figure 9.8 Partnerships and Collaborations: Distribution by Region
Figure 9.9 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Figure 9.10 Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Cumulative Distribution by Publication Year, 2018-2023
Figure 10.3 Patent Analysis: Distribution by Type of Patent and Publication Year
Figure 10.4 Patent Analysis: Distribution by Geography
Figure 10.5 Patent Analysis: Distribution by CPC Symbols
Figure 10.6 Leading Industry Players: Distribution by Number of Patents
Figure 10.7 Patent Analysis: Cumulative Distribution by Type of Organization
Figure 10.8 Leading Industrial Players: Benchmarking by Patent Characteristics (CPC Codes)
Figure 10.9 Patent Analysis: Distribution by Patent Age
Figure 10.10 Patent Analysis: Patent Valuation
Figure 11.1 Organic Nanoparticles: Number of Clinical Trials
Figure 11.2 Organic Nanoparticles: Extent of Innovation (Number of Patents)
Figure 11.3 Organic Nanoparticles: Trends in Research Activity (Number of Publications)
Figure 11.4 Nanoparticle Evaluation Framework: Organic Nanoparticles
Figure 11.5 Inorganic Nanoparticles: Number of Clinical Trials
Figure 11.6 Inorganic Nanoparticles: Extent of Innovation (Number of Patents)
Figure 11.7 Inorganic Nanoparticles: Trends in Research Activity (Number of Publications)
Figure 11.8 Nanoparticle Evaluation Framework: Inorganic Nanoparticles
Figure 11.9 Carbon-based Nanoparticles: Cumulative Number of Clinical Trials
Figure 11.10 Carbon-based Nanoparticles: Extent of Innovation (Number of Patents)
Figure 11.11 Carbon-based Nanoparticles: Trend in Research Activity (Number of Publications)
Figure 11.12 Nanoparticle Evaluation Framework: Carbon-based NanoparticlesFigure
Figure 11.13 Nanoparticle Evaluation Framework: Spider Web Representation
Figure 12.1 Global Nanoparticle Formulation Services Market, 2023-2035
Figure 12.2 Nanoparticle Formulation Services Market: Distribution by Type of Nanoparticle Formulated, 2023 and 2035
Figure 12.3 Nanoparticle Formulation Services Market: Distribution by Type of Organic Nanoparticle Formulated, 2023 and 2035
Figure 12.4 Nanoparticle Formulation Services Market for Polymeric Nanoparticles, 2023-2035 (USD Million)
Figure 12.5 Nanoparticle Formulation Services Market for Lipid Nanoparticles, 2023-2035 (USD Million)
Figure 12.6 Nanoparticle Formulation Services Market for Viral Nanoparticles, 2023-2035 (USD Million)
Figure 12.7 Nanoparticle Formulation Services Market for Protein-based Nanoparticles, 2023-2035 (USD Million)
Figure 12.8 Nanoparticle Formulation Services Market for Other Organic Nanoparticles, 2023-2035 (USD Million)
Figure 12.9 Nanoparticle Formulation Services Market for Inorganic Nanoparticles, 2023-2035 (USD Million)
Figure 12.10 Nanoparticle Formulation Services Market for Carbon-based Nanoparticles, 2023-2035 (USD Million)
Figure 12.11 Nanoparticle Formulation Services Market: Distribution by Scale of Operation, 2023 and 2035
Figure 12.12 Nanoparticle Formulation Services Market for Preclinical Operations, 2023-2035 (USD Million)
Figure 12.13 Nanoparticle Formulation Services Market for Clinical Operations, 2023-2035 (USD Million)
Figure 12.14 Nanoparticle Formulation Services Market for Commercial Operations, 2023-2035 (USD Million)
Figure 12.15 Nanoparticle Formulation Services Market: Distribution by Key Geographical Regions, 2023 and 2035
Figure 12.16 Nanoparticle Formulation Services Market in North America, 2023-2035 (USD Million)
Figure 12.17 Nanoparticle Formulation Services Market in Europe, 2023-2035 (USD Million)
Figure 12.18 Nanoparticle Formulation Services Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 12.19 Nanoparticle Formulation Services Market in Middle East and North Africa, 2023-2035 (USD Million)
Figure 12.20 Nanoparticle Formulation Services Market in Latin America, 2023-2035 (USD Million)
Figure 13.1 Licensing Agreements: Distribution of Financial Components
Figure 14.1 Concluding Remarks: Overall Technology Landscape
Figure 14.2 Concluding Remarks: Overall Service Providers Landscape
Figure 14.3 Concluding Remarks: Partnerships and Collaborations
Figure 14.4 Concluding Remarks: Patent Analysis
Figure 14.5 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

Table 4.1 Nanoparticle Formulation Technologies: Information on Type of Nanoparticle(s) Formulated
Table 4.2 Nanoparticle Formulation Technologies: Information on Formulation Method(s) Used
Table 4.3 Nanoparticle Formulation Technologies: Information on Type of Molecule(s) Delivered
Table 4.4 Nanoparticle Formulation Technologies: Information on Therapeutic Area(s)
Table 4.5 Nanoparticle Formulation Technologies: Information on Compatible Dosage Form(s)
Table 4.6 Nanoparticle Formulation Technologies: Information on Route(s) of Administration
Table 4.7 Nanoparticle Formulation Technologies: Information on Compatible Drug Release Mechanism
Table 4.8 Nanoparticle Formulation Technologies: Information on Compatibility for Long-Acting Drug Delivery
Table 4.9 Nanoparticle Formulation Technologies: List of Technology Developers
Table 5.1 Nanoparticle Formulation Service Providers: List of Service Providers
Table 5.2 Nanoparticle Formulation Service Providers: Information on Type of Nanoparticle(s) Formulated
Table 5.3 Nanoparticle Formulation Service Providers: Information on Type of Service(s) Offered
Table 5.4 Nanoparticle Formulation Service Providers: Information on Scale of Operation
Table 5.5 Nanoparticle Formulation Service Providers: Information on Application Area(s)
Table 8.1 Nanoparticle Formulation Technology Developers and Service Providers: List of Companies Profiled
Table 8.2 Ascension Sciences: Company Overview
Table 8.3 Ascension Sciences: Technology Portfolio
Table 8.4 Ascension Sciences: Recent Developments and Future Outlook
Table 8.5 DIANT Pharma: Company Overview
Table 8.6 DIANT Pharma: Technology Portfolio
Table 8.7 DIANT Pharma: Recent Developments and Future Outlook
Table 8.8 ExonanoRNA: Company Overview
Table 8.9 ExonanoRNA: Technology Portfolio
Table 8.10 ExonanoRNA: Recent Developments and Future Outlook
Table 8.11 Nanoform: Company Overview
Table 8.12 Nanoform: Technology Portfolio
Table 8.13 Nanoform: Recent Developments and Future Outlook
Table 8.14 NanoVation Therapeutics: Company Overview
Table 8.15 NanoVation Therapeutics: Technology Portfolio
Table 8.16 NanoVation Therapeutics: Recent Developments and Future Outlook
Table 8.17 NanoVelos: Company Overview
Table 8.18 NanoVelos: Technology Portfolio
Table 8.19 NTT Biopharma: Company Overview
Table 8.20 NTT Biopharma: Technology Portfolio
Table 8.21 Organoid-X BioTech: Company Overview
Table 8.22 Organoid-X BioTech: Technology Portfolio
Table 8.23 Vaxinano: Company Overview
Table 8.24 Vaxinano: Technology Portfolio
Table 8.25 Vaxinano: Recent Developments and Future Outlook
Table 9.1 Partnerships and Collaborations: Information on Year of Agreement, Type of Partnership and Type of Partner, 2018-2023
Table 9.2 Partnerships and Collaborations: Information on Type of Agreement (Country-wise and Continent-wise), 2018-2023
Table 10.1 Patent Analysis: List of Top CPC Sections
Table 10.2 Patent Analysis: List of Top CPC Symbols
Table 10.3 Patent Analysis: List of Top CPC Codes
Table 10.4 Patent Analysis: Categorizations based on Weighted Valuation Scores
Table 10.5 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 11.1 Organic Nanoparticles: Global Competition
Table 11.2 Inorganic Nanoparticles: Global Competition
Table 11.3 Carbon-based Nanoparticles: Global Competition
Table 13.1 Technology Licensing Deals
Table 16.1 Nanoparticle Formulation Technologies: Distribution by Type of Nanoparticle(s) Formulated
Table 16.2 Nanoparticle Formulation Technologies: Distribution by Type of Organic Nanoparticle(s) Formulated
Table 16.3 Nanoparticle Formulation Technologies: Distribution by Type of Inorganic Nanoparticle(s) Formulated
Table 16.4 Nanoparticle Formulation Technologies: Distribution by Type of Molecule(s) Delivered
Table 16.5 Nanoparticle Formulation Technologies: Distribution by Therapeutic Area(s)
Table 16.6 Nanoparticle Formulation Technologies: Distribution by Compatible Dosage Form(s)
Table 16.7 Nanoparticle Formulation Technologies: Distribution by Route(s) of Administration
Table 16.8 Nanoparticle Formulation Technology Developers: Distribution by Year of Establishment
Table 16.9 Nanoparticle Formulation Technology Developers: Distribution by Company Size
Table 16.10 Nanoparticle Formulation Technology Developers: Distribution by Location of Headquarters
Table 16.11 Nanoparticle Formulation Technology Developers: Distribution by Company Size and Location of Headquarters
Table 16.12 Most Active Players: Distribution by Number of Technologies
Table 16.13 Nanoparticle Formulation Service Providers: Distribution by Year of Establishment
Table 16.14 Nanoparticle Formulation Service Providers: Distribution by Company Size
Table 16.15 Nanoparticle Formulation Service Providers: Distribution by Location of Headquarters
Table 16.16 Nanoparticle Formulation Service Providers: Distribution by Company Size and Location of Headquarters
Table 16.17 Nanoparticle Formulation Service Providers: Distribution by Location of Facilities
Table 16.18 Nanoparticle Formulation Service Providers: Distribution by Type of Service Provider(s)
Table 16.19 Nanoparticle Formulation Service Providers: Distribution by Type of Nanoparticle(s) Formulated
Table 16.20 Nanoparticle Formulation Service Providers: Distribution by Type of Organic Nanoparticle(s) Formulated
Table 16.21 Nanoparticle Formulation Service Providers: Distribution by Type of Inorganic Nanoparticle(s) Formulated
Table 16.22 Nanoparticle Formulation Service Providers: Distribution by Type of Service Provider(s) and Type of Nanoparticle(s) Formulated
Table 16.23 Nanoparticle Formulation Service Providers: Distribution by Type of Service(s) Offered
Table 16.24 Nanoparticle Formulation Service Providers: Distribution by Company Size and Type of Service(s) Offered
Table 16.25 Nanoparticle Formulation Service Providers: Distribution by Scale of Operation
Table 16.26 Nanoparticle Formulation Service Providers: Distribution by Application Area(s)
Table 16.27 Partnerships and Collaborations: Distribution by Year of Partnership
Table 16.28 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.29 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 16.30 Partnerships and Collaborations: Distribution by Type of Partner
Table 16.31 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Table 16.32 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Headquarters of Partner
Table 16.33 Most Active Players: Distribution by Number of Partnerships
Table 16.34 Partnerships and Collaborations: Distribution by Region
Table 16.35 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Table 16.36 Partnerships and Collaborations: Distribution by Local and International Agreements
Table 16.37 Patent Analysis: Distribution by Type of Patent
Table 16.38 Patent Analysis: Cumulative Distribution by Publication Year, 2018-2023
Table 16.39 Patent Analysis: Distribution by Type of Patent and Publication Year
Table 16.40 Patent Analysis: Distribution by Geography
Table 16.41 Patent Analysis: Distribution by CPC Symbols
Table 16.42 Leading Industry Players: Distribution by Number of Patents
Table 16.43 Patent Analysis: Cumulative Distribution by Type of Organization
Table 16.44 Leading Industrial Players: Benchmarking by Patent Characteristics (CPC Codes)
Table 16.45 Patent Analysis: Distribution by Patent Age
Table 16.46 Organic Nanoparticles: Number of Clinical Trials
Table 16.47 Organic Nanoparticles: Extent of Innovation (Number of Patents)
Table 16.48 Organic Nanoparticles: Trends in Research Activity (Number of Publications)
Table 16.49 Inorganic Nanoparticles: Number of Clinical Trials
Table 16.50 Inorganic Nanoparticles: Extent of Innovation (Number of Patents)
Table 16.51 Inorganic Nanoparticles: Trends in Research Activity (Number of Publications)
Table 16.52 Carbon-based Nanoparticles: Cumulative Number of Clinical Trials
Table 16.53 Carbon-based Nanoparticles: Extent of Innovation (Number of Patents)
Table 16.54 Carbon-based Nanoparticles: Trends in Research Activity (Number of Publications)
Table 16.55 Global Nanoparticle Formulation Services Market, 2023-2035 (USD Billion)
Table 16.56 Nanoparticle Formulation Services Market: Distribution by Type of Nanoparticle Formulated, 2023 and 2035
Table 16.57 Nanoparticle Formulation Services Market: Distribution by Type of Organic Nanoparticle Formulated, 2023 and 2035
Table 16.58 Nanoparticle Formulation Services Market for Polymeric Nanoparticles, 2023-2035 (USD Million)
Table 16.59 Nanoparticle Formulation Services Market for Lipid Nanoparticles, 2023-2035 (USD Million)
Table 16.60 Nanoparticle Formulation Services Market for Viral Nanoparticles, 2023-2035 (USD Million)
Table 16.61 Nanoparticle Formulation Services Market for Protein-based Nanoparticles, 2023-2035 (USD Million)
Table 16.62 Nanoparticle Formulation Services Market for Other Organic Nanoparticles, 2023-2035 (USD Million)
Table 16.63 Nanoparticle Formulation Services Market for Inorganic Nanoparticles, 2023-2035 (USD Million)
Table 16.64 Nanoparticle Formulation Services Market for Carbon-based Nanoparticles, 2023-2035 (USD Million)
Table 16.65 Nanoparticle Formulation Services Market: Distribution by Scale of Operation, 2023 and 2035
Table 16.66 Nanoparticle Formulation Services Market for Preclinical Operations, 2023-2035 (USD Million)
Table 16.67 Nanoparticle Formulation Services Market for Clinical Operations, 2023-2035 (USD Million)
Table 16.68 Nanoparticle Formulation Services Market for Commercial Operations, 2023-2035 (USD Million)
Table 16.69 Nanoparticle Formulation Services Market: Distribution by Key Geographical Regions, 2023 and 2035
Table 16.70 Nanoparticle Formulation Services Market in North America, 2023-2035 (USD Million)
Table 16.71 Nanoparticle Formulation Services Market in Europe, 2023-2035 (USD Million)
Table 16.72 Nanoparticle Formulation Services Market in Asia-Pacific, 2023-2035 (USD Million)
Table 16.73 Nanoparticle Formulation Services Market in Middle East and North Africa 2023-2035 (USD Million)
Table 16.74 Nanoparticle Formulation Services Market in Latin America, 2023-2035 (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report:

  1. 20Med Therapeutics
  2. 2C Tech
  3. 2seventy bio
  4. 3SBio
  5. 4Clinics
  6. Abnova
  7. Abzena
  8. Accenture
  9. Acuitas Therapeutics
  10. Adipo Therapeutics
  11. Advanced NanoTherapies
  12. Afrigen Biologics
  13. Ajinomoto Bio-Pharma Services
  14. Aldevron
  15. Alpha Chitin
  16. AlphaRx
  17. AnteoTech 
  18. AnTolRx
  19. Aphios
  20. Applied Biomedical Science Institute
  21. Aprecia Pharmaceuticals
  22. Aquanova
  23. Aragen Life Sciences
  24. aratinga.bio (a subsidiary of Ixaka)
  25. Arbor Biotechnologies
  26. Arcline Investment Management
  27. Arcturus Therapeutics
  28. Ardena
  29. ARIZ Precision Medicine
  30. Arranta Bio
  31. Ascendia Pharmaceuticals
  32. Ascension Sciences
  33. Asklepios BioPharmaceutical
  34. Astellas Pharma
  35. AstraZeneca
  36. Aurora Vaccines
  37. Avanti Polar Lipids
  38. Avellino
  39. Baseimmune
  40. Baxter BioPharma Solutions
  41. BioConnection
  42. Biomedical Advanced Research and Development Authority (BARDA)
  43. Bionanoplus
  44. BioNTech
  45. Birdie Biopharmaceuticals (acquired by Seven and Eight Biopharmaceuticals)
  46. BOC Sciences
  47. Boehringer Ingelheim
  48. Bond Digital Health
  49. Bristol Myers Squibb
  50. Calando Pharmaceuticals
  51. CanSinoBIO
  52. CaPtivate Pharmaceuticals
  53. Carigent Therapeutics
  54. Catalent
  55. Cayman Chemical
  56. CD Bioparticles
  57. CD Formulation
  58. Celanese
  59. Celgene
  60. Cello Therapeutics
  61. Celonic
  62. Center for Applied Nanotechnology
  63. Centizyme
  64. Centre for Process Innovation (CPI)
  65. Ceramisphere Health
  66. Cerion
  67. Cerulean  
  68. Charité – Universitätsmedizin Berlin
  69. Chimeron Bio
  70. China Medical System (CMS)
  71. ClostraBio
  72. ConserV Bioscience
  73. CONTRACTOR BUSINESS CENTER
  74. CordenPharma
  75. Coriolis Pharma
  76. COUR Pharmaceuticals
  77. Covaris
  78. Creative Biolabs
  79. Cristal Therapeutics
  80. Croda
  81. CROmed Research
  82. CSL Seqirus
  83. Curapath
  84. CureVac
  85. Curia
  86. CuriRx
  87. Cytimmune Sciences
  88. Cytodiagnostics
  89. Danaher
  90. Delic Labs (formerly Complex Biotech Discovery)
  91. Delta 9 Cannabis
  92. DIANT Pharma
  93. Dolomite Microfluidics
  94. Duke-NUS Medical School
  95. Editas Medicine
  96. Elucida Oncology
  97. Emergent CDMO
  98. Encapsula NanoSciences
  99. Endo International
  100. Entos Pharmaceuticals
  101. enU Pharma
  102. Esco Aster
  103. etheRNA
  104. EUROAPI
  105. European Biotech Acquisition
  106. Evonik
  107. Evotec
  108. Exelead
  109. ExonanoRNA
  110. Expedeon (acquired by Abcam)
  111. Eyenovia
  112. Formosa Pharmaceuticals
  113. Formulogic Pharma
  114. FormuMax Scientific
  115. Fortis Life Sciences
  116. Fraunhofer Center for Applied Nanotechnology (CAN)
  117. Fujifilm
  118. GC Pharma
  119. GenEdit
  120. Genentech
  121. Genevant Sciences
  122. Genisphere
  123. Genprex
  124. Genuv
  125. George Mason University
  126. Ghent University
  127. Grand Pharmaceutical 
  128. Gritstone bio
  129. Harro Höfliger
  130. HCmed Innovations
  131. Herantis Pharma
  132. Hillstream BioPharma
  133. IMRA NanoBio
  134. IMUNON
  135. InnoUp
  136. Innovent
  137. InProcess-LSP
  138. Inside Therapeutics
  139. Integral Molecular
  140. Integrated Nanotherapeutics
  141. Intoolab (acquired by Metanomic)
  142. IoLiTec Ionic Liquids Technologies
  143. Ionic Pharmaceuticals
  144. Ironwood Pharmaceuticals
  145. Israeli Ministry of Health
  146. Istituto Biochimico Italiano (IBI)
  147. Ixaka
  148. JINIS Biopharmaceuticals
  149. Jixi Biotechnology
  150. Junshi Biosciences
  151. Kala Pharmaceuticals
  152. Lead Biotherapeutics
  153. Leiden Academic Centre for Drug Research
  154. Lemonex
  155. LEON
  156. LSNE Contract Manufacturing (a subsidiary of PCI Pharma Services)
  157. Luna Nanotech
  158. Macquarie University
  159. Mallinckrodt Pharmaceuticals
  160. Matinas BioPharma
  161. MDimune
  162. Medicines Patent Pool
  163. MedImmune (a subsidiary of AstraZeneca)
  164. MedLab Clinical
  165. Merck 
  166. Midatech Pharma
  167. MSD
  168. MyBiotech
  169. Myeloid Therapeutics
  170. N4 Pharma
  171. Nacuity Pharmaceuticals
  172. Nano Formulations
  173. Nano Gate
  174. Nanobrand
  175. NanoCarrier
  176. Nanocarry Therapeutics
  177. Nanochemazone
  178. Nanoco
  179. nanoComposix
  180. Nanoform
  181. NanoImaging Services
  182. Nanoligent
  183. NanOlogy
  184. Nanomerics
  185. Nano Research Elements
  186. Nanoscience Analytical
  187. Nanoscience Instruments
  188. Nanoshel
  189. Nanospectra Biosciences
  190. NanoSphaera
  191. Nanosphere Health Sciences
  192. Nanotechnology Characterization Laboratory (NCL)
  193. Nanotechnology Research Center
  194. NanoVation Therapeutics
  195. NanoVelos
  196. Nanovex Biotechnologies
  197. NanoViricides
  198. Nanox
  199. NANO-X
  200. National Institute of Allergy and Infectious Diseases (NIAID)
  201. National Institute of Neurological Disorders and Stroke (NINDS)
  202. National Resilience
  203. NeoVac
  204. Nestlé Health Science
  205. Novavax
  206. Novochizol
  207. NTT Biopharma
  208. NVIGEN
  209. Oculis
  210. Ocuphire Pharma
  211. OLM Diagnostics
  212. Operon
  213. Optimeos Life Sciences
  214. Organoid-X BioTech
  215. Orient EuroPharma (OEP)
  216. Orion
  217. Ovensa
  218. OZ Biosciences
  219. Pantherna Therapeutics
  220. Par Pharmaceutical
  221. Parvus Therapeutics
  222. PCI Pharma Services
  223. PDX Pharmaceuticals
  224. PendreaBio
  225. Pfizer
  226. Pharmanovia
  227. Phosphorex
  228. Piramal Pharma Solutions
  229. PlasmaChem
  230. PLiN Nanotechnology
  231. PolyMicrospheres
  232. Polymun Scientific
  233. Ponce Therapeutics
  234. Precision NanoSystems
  235. ProJect Pharmaceutics
  236. ProMab Biotechnologies
  237. PROVIREX Genome Editing Therapies
  238. Quotient Sciences
  239. QurCan Therapeutics (formerly known as Nanology Labs) 
  240. ReCode Therapeutics
  241. Replicate Bioscience
  242. Rexahn Pharmaceuticals
  243. RNA Nanotherapeutics
  244. Romer Labs
  245. Sarepta Therapeutics
  246. SciTech Development
  247. Seattle Genova
  248. Senda Biosciences
  249. SENTAN Pharma
  250. Serum Institute of India
  251. Sidney Kimmel Cancer Center - Jefferson Health
  252. Sirnaomics
  253. Siron
  254. SiSaf
  255. Siva Therapeutics
  256. SK Bioscience
  257. SOMA Bioscience
  258. Sona Nanotech
  259. Speratum Biopharma
  260. Stanipharm
  261. Starpharma
  262. Strides Pharma Science
  263. Sun Pharma Advanced Research Company (SPARC)
  264. Super Nano Design
  265. T&T Scientific
  266. Takeda Pharmaceutical
  267. Tandem Nano
  268. TargTex
  269. TechNanoIndia
  270. Tetra Bio-Pharma
  271. The Native Antigen
  272. The Plough Center - University of Tennessee 
  273. The University of Texas MD Anderson Cancer Center
  274. The University of Tokyo 
  275. Tianjin Chasesun Pharmaceutical
  276. TLC Biosciences
  277. Topas Therapeutics
  278. Toralgen
  279. True Amigo
  280. University of Birmingham
  281. University of Connecticut
  282. University of L’Aquila
  283. University of Pittsburgh
  284. University of Toronto
  285. Vaxinano
  286. Verily
  287. Verve Therapeutics
  288. ViiV Healthcare
  289. VinBiocare 
  290. VLP Therapeutics
  291. VSPARTICLE
  292. WACKER
  293. Walvax Biotechnology
  294. WIRB-Copernicus
  295. WuXi STA
  296. ZoneOne Pharma
  297. Zydus Healthcare

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com